Schwab Charles Investment Management Inc. lifted its stake in REGENXBIO Inc. (NASDAQ:RGNX) by 32.5% in the second quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 97,695 shares of the biotechnology company’s stock after purchasing an additional 23,971 shares during the quarter. Schwab Charles Investment Management Inc. owned about 0.32% of REGENXBIO worth $1,930,000 at the end of the most recent reporting period.
Several other institutional investors also recently made changes to their positions in the company. Strs Ohio boosted its holdings in shares of REGENXBIO by 6.4% in the 2nd quarter. Strs Ohio now owns 35,000 shares of the biotechnology company’s stock worth $691,000 after purchasing an additional 2,100 shares during the period. UBS Oconnor LLC purchased a new position in shares of REGENXBIO in the 1st quarter worth approximately $2,575,000. Goldman Sachs Group Inc. boosted its holdings in shares of REGENXBIO by 31.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 35,300 shares of the biotechnology company’s stock worth $681,000 after purchasing an additional 8,429 shares during the period. Tudor Investment Corp ET AL purchased a new position in shares of REGENXBIO in the 1st quarter worth approximately $979,000. Finally, Highbridge Capital Management LLC purchased a new position in shares of REGENXBIO in the 1st quarter worth approximately $965,000. Hedge funds and other institutional investors own 73.44% of the company’s stock.
RGNX has been the subject of a number of recent research reports. Chardan Capital reiterated a “buy” rating and issued a $75.00 target price (up previously from $55.00) on shares of REGENXBIO in a report on Tuesday, September 5th. Bank of America Corporation reiterated a “buy” rating and issued a $38.00 target price (up previously from $33.00) on shares of REGENXBIO in a report on Monday, October 9th. Zacks Investment Research cut REGENXBIO from a “buy” rating to a “hold” rating in a report on Thursday, August 17th. Raymond James Financial, Inc. began coverage on REGENXBIO in a report on Thursday, October 12th. They issued an “outperform” rating and a $39.00 target price for the company. Finally, Evercore ISI began coverage on REGENXBIO in a report on Wednesday, August 16th. They set an “outperform” rating and a $25.00 price objective for the company. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $40.00.
REGENXBIO Inc. (RGNX) opened at 30.50 on Wednesday. The company’s 50-day moving average price is $31.00 and its 200-day moving average price is $31.00. REGENXBIO Inc. has a 12-month low of $15.40 and a 12-month high of $36.10. The stock’s market cap is $942.27 million.
REGENXBIO (NASDAQ:RGNX) last posted its earnings results on Tuesday, August 8th. The biotechnology company reported ($0.47) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.81) by $0.34. The company had revenue of $6.56 million during the quarter. REGENXBIO had a negative return on equity of 38.74% and a negative net margin of 839.87%. On average, equities analysts expect that REGENXBIO Inc. will post ($2.93) EPS for the current fiscal year.
In other REGENXBIO news, insider Kenneth T. Mills sold 10,000 shares of the firm’s stock in a transaction on Friday, October 20th. The stock was sold at an average price of $32.62, for a total transaction of $326,200.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Vittal Vasista sold 3,040 shares of the firm’s stock in a transaction on Tuesday, August 15th. The stock was sold at an average price of $21.09, for a total value of $64,113.60. Following the sale, the chief financial officer now directly owns 103,118 shares of the company’s stock, valued at approximately $2,174,758.62. The disclosure for this sale can be found here. In the last three months, insiders have sold 210,040 shares of company stock valued at $5,874,639. 17.00% of the stock is owned by insiders.
REGENXBIO Company Profile
REGENXBIO Inc is a clinical-stage biotechnology company. The Company’s gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. The Company develops products candidates across the therapeutic areas of metabolic, neurodegenerative and retinal diseases.
Want to see what other hedge funds are holding RGNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for REGENXBIO Inc. (NASDAQ:RGNX).
Receive News & Ratings for REGENXBIO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REGENXBIO Inc. and related companies with MarketBeat.com's FREE daily email newsletter.